SG10201404101RA - Method For Producing Viral Vaccines - Google Patents

Method For Producing Viral Vaccines

Info

Publication number
SG10201404101RA
SG10201404101RA SG10201404101RA SG10201404101RA SG10201404101RA SG 10201404101R A SG10201404101R A SG 10201404101RA SG 10201404101R A SG10201404101R A SG 10201404101RA SG 10201404101R A SG10201404101R A SG 10201404101RA SG 10201404101R A SG10201404101R A SG 10201404101RA
Authority
SG
Singapore
Prior art keywords
viral vaccines
producing viral
producing
vaccines
viral
Prior art date
Application number
SG10201404101RA
Other languages
English (en)
Inventor
Otfried Kistner
Christa Tauer
Noel Barrett
Wolfgang Mundt
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of SG10201404101RA publication Critical patent/SG10201404101RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201404101RA 2007-08-28 2008-08-28 Method For Producing Viral Vaccines SG10201404101RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96672407P 2007-08-28 2007-08-28

Publications (1)

Publication Number Publication Date
SG10201404101RA true SG10201404101RA (en) 2014-09-26

Family

ID=39947984

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201404101RA SG10201404101RA (en) 2007-08-28 2008-08-28 Method For Producing Viral Vaccines

Country Status (17)

Country Link
US (2) US8497112B2 (ja)
EP (1) EP2192917B1 (ja)
JP (1) JP5535910B2 (ja)
KR (1) KR101760844B1 (ja)
CN (1) CN101790381B (ja)
AU (1) AU2008293513B2 (ja)
BR (1) BRPI0816130A2 (ja)
CA (1) CA2696090C (ja)
ES (1) ES2459166T3 (ja)
HK (1) HK1143328A1 (ja)
HR (1) HRP20140375T1 (ja)
IL (1) IL203869A (ja)
PL (1) PL2192917T3 (ja)
RU (1) RU2496519C2 (ja)
SG (1) SG10201404101RA (ja)
SI (1) SI2192917T1 (ja)
WO (1) WO2009029695A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
BRPI0618254A2 (pt) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
EP2185191B1 (en) * 2007-06-27 2012-09-12 Novartis AG Low-additive influenza vaccines
ES2608841T3 (es) 2009-02-10 2017-04-17 Seqirus UK Limited Vacunas contra la gripe con cantidades reducidas de escualeno
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
GB0918830D0 (en) * 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
BR112012027643A2 (pt) * 2010-05-03 2016-08-16 Glaxosmithkline Biolog Sa métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2663327A4 (en) 2011-01-13 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
JP6275641B2 (ja) * 2011-07-20 2018-02-07 ビージーピー プロダクツ ベー ブイ ウイルス抗原およびワクチンの製造方法
EP2737060B1 (en) * 2011-07-27 2019-03-06 Flash Therapeutics Method for the production of retroviral particles useful for transducing eukaryotic cells
EP2780350B1 (en) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2894467A1 (en) 2012-01-27 2013-08-01 Variation Biotechnologies Inc. Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
JP6522606B2 (ja) * 2013-10-22 2019-05-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 乾燥血斑からの細胞遊離性ウイルス粒子の測定方法
FR3025107B1 (fr) * 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
CN111979120B (zh) * 2019-05-23 2022-09-27 比欧联科供应链管理(北京)有限公司 一种狂犬疫苗核酸消化去除装置及实验方法
RU2754398C1 (ru) * 2020-06-25 2021-09-01 Общество с ограниченной ответственностью «ФОРТ» Способ получения четырехвалентной вакцины для профилактики гриппа

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (ja) * 1974-01-14 1977-07-15 Sandoz Ag
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
FR2533548B1 (fr) * 1982-09-28 1985-07-26 Degremont Procede et appareil de traitement anaerobie d'eaux residuaires dans un filtre a remplissage de materiau granulaire
EP0172433A3 (en) * 1984-08-02 1989-04-05 Tektronix, Inc. Display method and apparatus employing cursor panning
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
RU2082433C1 (ru) * 1992-07-13 1997-06-27 Николай Владимирович Костючек Способ вакцинопрофилактики гриппа
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
CN1223589A (zh) * 1996-05-06 1999-07-21 美国拜尔公司 包含鹦鹉热衣原体的猫疫苗及其制备方法
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
TWI227274B (en) * 1998-10-05 2005-02-01 Univ Osaka Res Found Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
ATE422364T1 (de) * 1998-12-17 2009-02-15 Sanofi Pasteur Ltd Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
WO2002009702A2 (en) 2000-07-28 2002-02-07 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
RU2195959C1 (ru) * 2001-11-02 2003-01-10 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Инактивированная вакцина против синдрома гидроперикардита кур
RU2261111C1 (ru) * 2004-04-08 2005-09-27 Сергеев Виталий Александрович Инактивированная вакцина против вирусных пневмогастроэнтеритов крупного рогатого скота и телят и способ профилактики вирусных пневмогастроэнтеритов
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine

Also Published As

Publication number Publication date
HRP20140375T1 (hr) 2014-06-20
RU2496519C2 (ru) 2013-10-27
JP5535910B2 (ja) 2014-07-02
EP2192917A1 (en) 2010-06-09
KR20100075865A (ko) 2010-07-05
IL203869A (en) 2016-05-31
US20130287811A1 (en) 2013-10-31
US8497112B2 (en) 2013-07-30
RU2010111747A (ru) 2011-10-10
PL2192917T3 (pl) 2014-06-30
CA2696090A1 (en) 2009-03-05
CN101790381A (zh) 2010-07-28
ES2459166T3 (es) 2014-05-08
JP2010537641A (ja) 2010-12-09
CA2696090C (en) 2017-06-13
WO2009029695A1 (en) 2009-03-05
BRPI0816130A2 (pt) 2015-02-24
AU2008293513A1 (en) 2009-03-05
EP2192917B1 (en) 2014-01-29
CN101790381B (zh) 2014-08-27
KR101760844B1 (ko) 2017-07-24
HK1143328A1 (en) 2010-12-31
SI2192917T1 (sl) 2014-05-30
AU2008293513B2 (en) 2013-11-21
US20090060950A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
HK1143328A1 (en) Method for producing viral vaccines
ZA202006532B (en) Method for decreasing immunogenicity
IL237406A0 (en) Improved methods for the production of yeast-based vaccines
ZA201001480B (en) Method for producing flu virus
GB0700136D0 (en) Process for manufacturing vaccines
IL238437A (en) Method for Preparation of 3-Aryl-5-Trifluoromethyl-5,4-Dihydro-Isoxazoles
PL2200646T3 (pl) Szczepionki RNA
PL2252691T3 (pl) Sposób otrzymywania alfa-santalenu
ZA201102424B (en) Process for preparing 2-alkyl-3-aroyl-5-nitro-benzofurans
EP2474560A4 (en) METHOD OF PREPARING AN 11 SUGAR SIALYLOLIGOSACCHARIDE PEPTIDE
HK1149037A1 (en) Method for producing microporous sheet
PL1970396T3 (pl) Sposób przygotowania polieterosiloksanów związanych wiązaniem SiC
HRP20150775T1 (en) Method for preparing hypoallergens
EP2374789A4 (en) METHOD FOR PRODUCING BETA-ALKOXYPROPIONAMIDE
ZA201004304B (en) Vaccines for malaria
EP2221306A4 (en) PROCESS FOR PREPARING 2-AZAADAMANTANE
EP2068904A4 (en) METHODS FOR PREPARING DIAZONAMIDES
EP2351835A4 (en) PROCESS FOR PREPARING CLEANED INFLUENZA VIRUS ANTIGENES
GB2456999B (en) Method for preparing 2-deoxy-L-ribose
IL210051A0 (en) Method for producing aminobiphenylene
IL207222A0 (en) Process for preparing hebivolol
EP2357247A4 (en) PROCESS FOR THE PRODUCTION OF POLY-3-HYDROXYALKANOATE
EP2259269A4 (en) METHOD FOR MANUFACTURING RADIOACTIVE STRONTIUM
GB0706912D0 (en) Novel viral vaccines
IL210353A0 (en) Method for producing phenylalkane - 1 - ols